The Diagnostic Ability of Follow-Up Imaging Biomarkers after
Treatment of Glioblastoma in the Temozolomide Era: Implications
from Proton MR Spectroscopy and Apparent Diffusion Coefficient
Mapping

J 2015

The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

BULIK, Martin, Tomáš KAZDA, Pavel ŠLAMPA and Radim JANČÁLEK

Basic information

Original name

The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

Authors

BULIK, Martin (203 Czech Republic, guarantor, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution) and Radim JANČÁLEK (203 Czech Republic, belonging to the institution)

Edition

Biomed Research International, New York, Hindawi Publishing Corporation, 2015, 2314-6133

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.134

RIV identification code

RIV/00216224:14110/15:00085175

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1155/2015/641023

UT WoS

000362030700001

Keywords in English

choline; creatine; lactic acid; n acetylaspartic acid; temozolomide

Abstract

V originále

Objective. To prospectively determine institutional cut-off values of apparent diffusion coefficients (ADCs) and concentration of tissue metabolites measured by MR spectroscopy (MRS) for early differentiation between glioblastoma (GBM) relapse and treatment-related changes after standard treatment. Materials and Methods. Twenty-four GBM patients who received gross total resection and standard adjuvant therapy underwent MRI examination focusing on the enhancing region suspected of tumor recurrence. ADC maps, concentrations of N-acetylaspartate, choline, creatine, lipids, and lactate, and metabolite ratios were determined. Final diagnosis as determined by biopsy or follow-up imaging was correlated to the results of advanced MRI findings. Results. Eighteen (75%) and 6 (25%) patients developed tumor recurrence and pseudoprogression, respectively. Mean time to radiographic progression from the end of chemoradiotherapy was 5.8 +/- 5.6 months. Significant differences in ADC and MRS data were observed between those with progression and pseudoprogression. Recurrence was characterized by N-acetylaspartate <= 1.5mM, choline/N-acetylaspartate >= 1.4 (sensitivity 100%, specificity 91.7%), N-acetylaspartate/creatine <= 0.7, and ADC <= 1300 x 10(-6) mm(2)/s (sensitivity 100%, specificity 100%). Conclusion. Institutional validation of cut-off values obtained from advanced MRI methods is warranted not only for diagnosis of GBM recurrence, but also as enrollment criteria in salvage clinical trials and for reporting of outcomes of initial treatment.

Citovat

BULIK, Martin, Tomáš KAZDA, Pavel ŠLAMPA and Radim JANČÁLEK. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping. Biomed Research International. New York: Hindawi Publishing Corporation, 2015, vol. 2015, No 641023, p. 1-9. ISSN 2314-6133. Available from: https://dx.doi.org/10.1155/2015/641023.

@article{1320633,
   author = {Bulik, Martin and Kazda, Tomáš and Šlampa, Pavel and Jančálek, Radim},
   article_location = {New York},
   article_number = {641023},
   doi = {http://dx.doi.org/10.1155/2015/641023},
   keywords = {choline; creatine; lactic acid; n acetylaspartic acid; temozolomide},
   language = {eng},
   issn = {2314-6133},
   journal = {Biomed Research International},
   title = {The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping},
   volume = {2015},
   year = {2015}
}

TY  - JOUR
ID  - 1320633
AU  - Bulik, Martin - Kazda, Tomáš - Šlampa, Pavel - Jančálek, Radim
PY  - 2015
TI  - The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping
JF  - Biomed Research International
VL  - 2015
IS  - 641023
SP  - 1-9
EP  - 1-9
PB  - Hindawi Publishing Corporation
SN  - 23146133
KW  - choline
KW  - creatine
KW  - lactic acid
KW  - n acetylaspartic acid
KW  - temozolomide
N2  - Objective. To prospectively determine institutional cut-off values of apparent diffusion coefficients (ADCs) and concentration of tissue metabolites measured by MR spectroscopy (MRS) for early differentiation between glioblastoma (GBM) relapse and treatment-related changes after standard treatment. Materials and Methods. Twenty-four GBM patients who received gross total resection and standard adjuvant therapy underwent MRI examination focusing on the enhancing region suspected of tumor recurrence. ADC maps, concentrations of N-acetylaspartate, choline, creatine, lipids, and lactate, and metabolite ratios were determined. Final diagnosis as determined by biopsy or follow-up imaging was correlated to the results of advanced MRI findings. Results. Eighteen (75%) and 6 (25%) patients developed tumor recurrence and pseudoprogression, respectively. Mean time to radiographic progression from the end of chemoradiotherapy was 5.8 +/- 5.6 months. Significant differences in ADC and MRS data were observed between those with progression and pseudoprogression. Recurrence was characterized by N-acetylaspartate <= 1.5mM, choline/N-acetylaspartate >= 1.4 (sensitivity 100%, specificity 91.7%), N-acetylaspartate/creatine <= 0.7, and ADC <= 1300 x 10(-6) mm(2)/s (sensitivity 100%, specificity 100%). Conclusion. Institutional validation of cut-off values obtained from advanced MRI methods is warranted not only for diagnosis of GBM recurrence, but also as enrollment criteria in salvage clinical trials and for reporting of outcomes of initial treatment.
ER  -

BULIK, Martin, Tomáš KAZDA, Pavel ŠLAMPA and Radim JANČÁLEK. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping. \textit{Biomed Research International}. New York: Hindawi Publishing Corporation, 2015, vol.~2015, No~641023, p.~1-9. ISSN~2314-6133. Available from: https://dx.doi.org/10.1155/2015/641023.

Detailed Information on Publication Record